Last reviewed 2026-04-23 · How we verify

Drug: Dose -SM-88

Pancreatic Cancer Action Network · Phase 3 active Small molecule

Drug: Dose -SM-88 is a Metabolic modulator Small molecule drug developed by Pancreatic Cancer Action Network. It is currently in Phase 3 development for Pancreatic cancer (in combination with gemcitabine and nab-paclitaxel).

SM-88 is a metabolic modulator that inhibits cancer cell metabolism by targeting key enzymes involved in glucose and amino acid utilization.

SM-88 is a metabolic modulator that inhibits cancer cell metabolism by targeting key enzymes involved in glucose and amino acid utilization. Used for Pancreatic cancer (in combination with gemcitabine and nab-paclitaxel).

At a glance

Generic name	Drug: Dose -SM-88
Sponsor	Pancreatic Cancer Action Network
Drug class	Metabolic modulator
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

SM-88 works by disrupting the metabolic pathways that cancer cells depend on for survival and proliferation, particularly targeting glycolysis and amino acid metabolism. By inhibiting these metabolic processes, the drug aims to starve cancer cells of the energy and building blocks they need to grow. This metabolic approach is designed to work synergistically with standard chemotherapy agents.

Approved indications

Pancreatic cancer (in combination with gemcitabine and nab-paclitaxel)

Common side effects

Gastrointestinal toxicity
Fatigue
Nausea

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Drug: Dose -SM-88 CI brief — competitive landscape report
Drug: Dose -SM-88 updates RSS · CI watch RSS
Pancreatic Cancer Action Network portfolio CI

Frequently asked questions about Drug: Dose -SM-88

What is Drug: Dose -SM-88?

Drug: Dose -SM-88 is a Metabolic modulator drug developed by Pancreatic Cancer Action Network, indicated for Pancreatic cancer (in combination with gemcitabine and nab-paclitaxel).

How does Drug: Dose -SM-88 work?

SM-88 is a metabolic modulator that inhibits cancer cell metabolism by targeting key enzymes involved in glucose and amino acid utilization.

What is Drug: Dose -SM-88 used for?

Drug: Dose -SM-88 is indicated for Pancreatic cancer (in combination with gemcitabine and nab-paclitaxel).

Who makes Drug: Dose -SM-88?

Drug: Dose -SM-88 is developed by Pancreatic Cancer Action Network (see full Pancreatic Cancer Action Network pipeline at /company/pancreatic-cancer-action-network).

What drug class is Drug: Dose -SM-88 in?

Drug: Dose -SM-88 belongs to the Metabolic modulator class. See all Metabolic modulator drugs at /class/metabolic-modulator.

What development phase is Drug: Dose -SM-88 in?

Drug: Dose -SM-88 is in Phase 3.

What are the side effects of Drug: Dose -SM-88?

Common side effects of Drug: Dose -SM-88 include Gastrointestinal toxicity, Fatigue, Nausea.

Drug class: All Metabolic modulator drugs
Manufacturer: Pancreatic Cancer Action Network — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Pancreatic cancer (in combination with gemcitabine and nab-paclitaxel)
Compare: Drug: Dose -SM-88 vs similar drugs
Pricing: Drug: Dose -SM-88 cost, discount & access